Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment
- PMID: 30081609
- PMCID: PMC6121470
- DOI: 10.3390/ijms19082299
Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment
Abstract
Signal transducer and activator of transcription (STAT) 3 plays a central role in the host response to injury. It is activated rapidly within cells by many cytokines, most notably those in the IL-6 family, leading to pro-proliferative and pro-survival programs that assist the host in regaining homeostasis. With persistent activation, however, chronic inflammation and fibrosis ensue, leading to a number of debilitating diseases. This review summarizes advances in our understanding of the role of STAT3 and its targeting in diseases marked by chronic inflammation and/or fibrosis with a focus on those with the largest unmet medical need.
Keywords: Crohn’s disease (CD); STAT3; asthma; cachexia; fibrosis; inflammatory bowel disease (IBD); ulcerative colitis (UC).
Conflict of interest statement
Baylor College and Medicine, with David Tweardy as inventor, has filed 19 patents covering the use of C188-9, a small-molecule inhibitor of STAT3 cited in this review. These patents are exclusively licensed to Tvardi Therapeutics, Inc., which was founded and is co-owned by David Tweardy.
Figures
References
-
- Caiello I., Minnone G., Holzinger D., Vogl T., Prencipe G., Manzo A., De Benedetti F., Strippoli R. IL-6 amplifies TLR mediated cytokine and chemokine production: Implications for the pathogenesis of rheumatic inflammatory diseases. PLoS ONE. 2014;9:e107886. doi: 10.1371/journal.pone.0107886. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
